Medication info
Vivas Tablet 10/40 mg

Vivas Tablet 10/40 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›13.888mg / 1 tablet
Manufacturer / importer
Daehwa Pharmaceutical Co., Ltd.
Appearance
Dark red, round film-coated tablet
Packaging
28 tablets/box [14 tablets/blister x 2]
Approval status
Active

MFDS item code 201404765 · Approved 2014.10.17 · Insurance code 645604470

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet of this medicine once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended for patients with moderate renal impairment. ○ Patients with reduced effective circulating blood volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose with careful monitoring of their condition. ○ Patients with hepatic impairment: Use caution when administering this medicine to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this medicine, under Precautions for Use.) ○ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
○ Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Daehwa Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Amlodipine or olmesartan medoxomil is used to treat essential hypertension. These medications effectively lower blood pressure and help reduce cardiovascular risk. They are particularly useful for patients who have difficulty controlling blood pressure and are prescribed when blood pressure is not adequately managed with monotherapy. Regular use can prevent complications arising from hypertension. These agents safely dilate blood vessels to improve blood pressure.

How to take

Adult dose

Take 1 tablet of this medicine once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended for patients with moderate renal impairment. ○ Patients with reduced effective circulating blood volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose with careful monitoring of their condition. ○ Patients with hepatic impairment: Use caution when administering this medicine to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this medicine, under Precautions for Use.) ○ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

○ Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Do not take if you have allergies to the active ingredients or similar medications, are pregnant or breastfeeding, have severe liver disease or specific heart conditions, biliary obstruction, are undergoing kidney dialysis, are in shock, have certain types of diabetes, or have severe kidney impairment. Patients with depleted fluid or salt may experience hypotension at the onset of treatment, thus careful monitoring of their condition is necessary, and appropriate measures should be taken if hypotension occurs. Severe aortic stenosis patients should be cautious as rapid vasodilation can lead to hypotension. Patients with severe obstructive coronary artery disease should be careful, as angina or myocardial infarction may worsen during treatment. Use cautiously in patients with congestive heart failure, monitoring for exacerbation of heart failure symptoms during therapy. Patients with impaired renal function may experience further deterioration of renal function from this medication, hence caution is advised. In patients with liver impairment, dosage adjustment and careful monitoring are critical as this medication may remain in the liver for extended periods. Common side effects include dizziness, headache, hypotension, swelling, fatigue, dyspepsia, etc., with rare occurrences of skin rashes or myalgia. This medication may interact with other antihypertensive medications or specific drugs, so it is essential to inform your doctor or pharmacist of any other medications you are taking. This medication is generally not used during pregnancy, and nursing mothers should consider stopping breastfeeding or the medication itself due to potential effects on the baby. Safety and efficacy have not been established in children under 18 years. Elderly patients may experience increased drug concentration due to decreased renal and liver function; starting with a lower dose and careful monitoring of their condition is recommended. Overdose may result in severe hypotension, vasodilation, or tachycardia, requiring immediate medical attention.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • sensory deficiency
  • syncope
Show 84 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • lower back pain
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • exacerbation of cerebral infarction
  • gum bleeding
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • diplopia
  • insomnia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • increased serum creatinine
  • hyperkalemia
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • bradycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is crucial to maintain a room temperature between 1 degree and 30 degrees Celsius to preserve the medication's efficacy and safety over time.

Appearance and packaging

Appearance

Dark red, round film-coated tablet

Package unit

28 tablets/box [14 tablets/blister x 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.